EPISODE · Mar 10, 2026 · 1 MIN
ACT Brief: Bayesian Shifts Regulatory Culture, Quality Tolerance Limits Drive Risk Management, CBER Leadership Changes
from Applied Clinical Trials · host Applied Clinical Trials
In today's ACT Brief, we explore how Bayesian methods are reshaping FDA interactions and trial design, quality tolerance limits are becoming operational guardrails in risk-based quality management, and leadership transitions at the FDA's Center for Biologics Evaluation and Research signal evolving regulatory priorities.
Embed this episode
Ready to play
ACT Brief: Bayesian Shifts Regulatory Culture, Quality Tolerance Limits Drive Risk Management, CBER Leadership Changes
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.